Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials

This publication has 36 references indexed in Scilit:

• Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies
  European Journal Of Cancer, 1996
• A comparison of two phase I trial designs
  Statistics in Medicine, 1994
• Phase I clinical trials: Adapting methodology to face new challenges
  Annals of Oncology, 1994
• Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer Agents
  JNCI Journal of the National Cancer Institute, 1993
• Model-Guided Determination of Maximum Tolerated Dose in Phase I Clinical Trials: Evidence for Increased Precision
  JNCI Journal of the National Cancer Institute, 1993
• The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies
  Annals of Oncology, 1992
• Using toxicity grades in the design and analysis of cancer phase i clinical trials
  Statistics in Medicine, 1992
• EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents
  European Journal of Cancer and Clinical Oncology, 1991
• A Monte Carlo comparison of three up-and-down designs for dose ranging
  Controlled Clinical Trials, 1983
• Transplacental Carcinogenesis by Stilbestrol
  New England Journal of Medicine, 1971